treated like syphilis and included in routine antenatal screening, with resources concentrated on counselling after testing for women found to be positive. 1 There is little discussion or information given before antenatal syphilis screening.
2 Between 1994 and 1997, 121 women with syphilis were detected in the UK through antenatal screening.
3 Do we know how those women felt about being given this result, what the impact was on their lives? The consequences of being given a positive HIV result are more complex. Although compulsory testing is frowned upon, 4 testing where women may not be aware of what they are being tested for and are then confronted with a positive result, has the same eVect. Applying "informed right of refusal" only benefits those who are already articulate and assertive.
The study by Gibb et al, 5 quoted by Nicoll, showed that women exposed in Africa and those who had a partner who was black African had the lowest uptakes for screening (comparable with women of low risk), despite being at higher risk of infection. Acceptability of a test and provision of information are crucial prerequisites for a successful screening programme. My work over the past 10 years with women and HIV/AIDS in Southern Africa, taught me that a label of HIV positive brings shame, desertion, poverty, stigma, and distress. Women will often try to "normalise" their lives by denying the possibility of exposure as long as possible. When examining uptake of HIV screening in antenatal care among women of African origin, it would be better to look to the literature from their own background rather than extrapolating from studies with other risk groups, such as intravenous drug users. Pregnant women are not all the same and have diVerent needs, peer pressures, and support systems within which they have to deal with being tested.
The BMJ special issue on antenatal HIV testing (24 Jan 1998) reported several possible mechanisms for increasing uptake for screening, including leaflets and information emphasising the benefits of testing, 6 short specific information given by midwives before testing, 6 and attention to the quality and approach of diVerent midwives.
7 None of these interventions has been provided at present for antenatal syphilis screening, yet would contribute to the acceptability of both tests. They would have the advantage of giving women informed choices, retaining their pride and self esteem. Women would have the opportunity to ask for more specific information in depth, and, if the test were positive, to have identified support to guide them through the maze of treatments and surgical interventions. Screening would thereby benefit them as well as their present and future oVspring. Author's reply Dr Ray makes some important points which should be considered when attempting to enhance the level of voluntary, confidential HIV testing in pregnancy in the UK. However, her letter starts with a false premise. The article she comments upon does not argue at any point for HIV testing to be conducted in the manner that syphilis testing is often done in the UK-that is, automatically and without the mother's knowledge. 1 Dr Ray is wholly right in arguing that women's knowledge about syphilis testing (not mentioned in the original article) should be improved to the desired standards of antenatal HIV testing, rather than the converse. Indeed that was within the first recommendation of a recent PHLS report on antenatal syphilis screening.
SUNANDA RAY

2
Dr Ray is correct that the diVerent cultural needs of women receiving antenatal care have to be taken into consideration and, certainly, no woman should be tested against her will. But those providing antenatal care are already experienced in routinely providing other screening tests-for example, for Down's syndrome and diYcult haemoglobinopathies. The 1998 Intercollegiate Working Party Guidelines, which serve as the current working recommendations for antenatal HIV testing, emphasise the importance of taking cultural factors into account in four of their 20 recommendations.
3 These evidence based guidelines drew heavily on the data in the articles in the 24 January 1998 special issue of the BMJ, which were available to the working party members. These four points also arose from the working party's consultation with black African women's groups. It is possible to overemphasise the importance of particular cultural connections, however, to the point where professionals feel afraid to oVer routine screening tests to minority groups. The striking point about the study by Gibb et al was not that black African women had the lowest uptake of HIV testing (in fact they did not, the lowest uptake was among south Asians), but that the African women and the majority white women had similar uptakes.
4 Also, once they know their infection status HIV positive black African pregnant women in London are as willing as other women to use methods of reducing their risk of their child becoming HIV infected. As was documented in the BMJ special issue and this journal, the greatest constraint on levels of antenatal HIV testing in London has not been any special cultural need of particular groups of women, but the view of professional staV that HIV testing was especially diYcult to take on.
1 Hence whether or not a woman was oVered HIV testing was a lottery, depending on which hospital she attended, or which particular professional she saw.
7
Paradoxically, the group most likely to benefit, black African women, lost the most in this process. There are indications that these attitudes are beginning to be overcome, resulting in a modest increase in identification of HIV infected women in pregnancy in London. 8 What is now apparent is that HIV testing should be delivered as part of a routine package of antenatal tests. Experience in the UK is that this approach reduces the anxiety of those being tested, and those providing testing, but it does not result in a 100% uptake.
9 Women are aware they are being tested for HIV, informed refusal is preserved, but is refused by only a minority of women.
The next constraint is antiquated information technology. It is proving peculiarly diYcult to obtain routinely basic information about the percentage of women who received or were oVered HIV testing in pregnancy, let alone how these statistics can be broken down by obstetric team, midwife, general practice, etc (Bedford H, personal communication). Investment is urgently needed to modernise many maternity information systems so that they can provide these basic programme monitoring data. To return to Dr Ray's original point, this would benefit all screening in pregnancy, not just testing for HIV infection. 
ANGUS NICOLL
Timely neonatal screening
In their recent paper Ades et al showed that any improvement to timely neonatal screening strategy should consider all the steps, from sample collection to the follow up of detected cases.
1 EYcient neonatal screening programmes for metabolic disease, by screening large numbers of samples, have to detect patients who will require prompt follow up. In particular, the introduction of new tests for life threatening conditions, such as congenital adrenal hyperplasia, allows programmes to reconsider the timeliness of the procedures.
In France the question arose 10 years ago, when screening for congenital adrenal hyperplasia was considered. Before such screening could be implemented the French Association for Neonatal Screening asked screening centres to show that they could determine 17 -hydroxyprogesterone (17 -OHP) within 12 days of birth, because the expert committee estimated that salt loss crisis can be observed from two weeks after birth.
To fulfil this prerequisite, changes in the management of samples were necessary: 1 Dried blood samples had to be collected at day 3 (not before the 72nd hour of life, to avoid the risk of a false negative result for phenylketonuria screening) 2 Samples were posted on the same day as collection by "first class mail" and included a prestamped envelope. (The screening centres pay the postal services directly for these) 3 The priority of analysis was modified and 17 -OHP was determined on arrival. In our laboratory periodic monitoring of the timeliness of screening is performed. Figure 1 shows data observed before and after these changes for time intervals between birth, collection of sample, and date of the sample arriving at the laboratory. In 1998 76.5% of samples were collected by day 3 and 96.5% by day 4, illustrating that the recommendations were well understood. Postal delays have also been significantly reduced (five days for 94%), and 95.3% of samples were in the laboratory by day 9. Samples are received in the laboratory at 8 00 am and analysed on the day of arrival. The results are available on the same day for phenylalanine (fluorometry) and the next day for thyroid stimulating hormone and 17 -OHP (overnight incubation, Delfia methods). Consequently, the total time between birth and reading the results is 10 days for 94.5% of samples, with a five day week.
Our experience shows that the optimisation of screening strategy proposed by Ades et al works routinely. Inevitably, such a strategy will have a cost; in our case an extra 1.30 FF (0.2 Euro) to cover postage, which represents 3.9% of the total test cost for each baby (including filter paper cards, analysis, salaries, etc). Before 1988
